This paper explores European and national trends in specialised drug treatment entry for cannabis-related problems. The analysis is based on data for the years 2003-2014 from 22 European countries. Between 2003 and 2014, the overall number and proportion of primary cannabis-related first-time entrants increased significantly. A joinpoint regression analysis indicates that the overall increase of cannabis treatment entries is continuous, although country-related differences are observed. Possible explanations for the increase and different time trends are discussed including an increase in cannabis prevalence and cannabis-related problems, changes in risk perception, increases in cannabis potency, changes in referral practices and increased availability and accessibility of treatment services.

Journal Section:
Editor's choice
Keywords:
Cannabis, Treatment entries, Trends, Europe, Joinpoint regression
1.
UNODC: World Drug Report 2016. New York, 2016, p 105.
2.
European Monitoring Centre for Drugs and Drug Addiction: European Drug Report 2016: Trends and Developments. Lisbon, EMCDDA, 2016. http://www.emcdda.europa.eu/edr2016.
3.
EMCDDA: 2016 Statistical Bulletin, 2016.
4.
Hall W, Degenhardt L, Lynskey M: Ageing CD of H and: The health and psychological effects of cannabis use. Monogr Ser 2001;182.
5.
WHO: The Health and Social Effects of Nonmedical Cannabis Use. 2016. http://who.int/substance_abuse/publications/msbcannabis.pdf?ua=1.
6.
United Nations Office on Drugs and Crimes: Discussion Paper Cannabis A Short Review, 2012, pp 1-29.
7.
EMCDDA: A Cannabis Reader: Global Issues and Local Experiences. 2008. http://www.emcdda.europa.eu.
8.
EMCDDA: Treatment Demand Indicator Standard Protocol 3.0, 2012.
9.
EMCDDA: TDI Methodological Information on 30 European Countries Methods and Definitions of TDI Data Reported to the EMCDDA in 2014, 2014.
10.
Schettino J, Leuschner F, Kasten L, Tossman P: Treatment of Cannabis-Related Disorders in Europe. 2015 (http://www.emcdda.europa.eu/attachements.cfm).
11.
Institute NC: Joint Point Regression, 2015.
12.
Griffiths P, Mounteney J, Laniel L: Understanding changes in heroin availability in Europe over time: emerging evidence for a slide, a squeeze and a shock. Addiction 2012;107:1539-1540.
[PubMed]
https://doi.org/10.1111/j.1360-0443.2012.03829.x
13.
Rush B, Urbanoski K: Estimating the demand for treatment for cannabis-related problems in Canada. Int J Ment Health Addict 2007;5:181-186.
https://doi.org/10.1007/s11469-007-9061-0
14.
EMCDDA: European Drug Report 2016. Lisbon, EMCDDA, 2016. http://www.emcdda.europa.eu/edr2016.
15.
EMCDDA: Annual Report 2005: State of the Drugs Problem in Europe, 2005, p 96.
16.
Barrio G, Montanari L, Bravo MJ, Guarita B, de la Fuente L, Pulido J, et al: Trends of heroin use and heroin injection epidemics in Europe: findings from the EMCDDA treatment demand indicator (TDI). J Subst Abuse Treat 2013;45:19-30.
[PubMed]
https://doi.org/10.1016/j.jsat.2012.11.002
17.
Roxburgh A, Hall WD, Degenhardt L, McLaren J, Black E, Copeland J, et al: The epidemiology of cannabis use and cannabis-related harm in Australia 1993-2007. Addiction 2010;105:1071-1079.
[PubMed]
https://doi.org/10.1111/j.1360-0443.2010.02903.x
18.
Sánchez-Niubò A, Sordo L, Fortiana J, Brugal MT, Domingo-Salvany A: Incidence trends of cannabis and cocaine use from periodic Spanish general population surveys: effect of standardizing results by age structure. Addiction 2013;108:1450-1458.
[PubMed]
https://doi.org/10.1111/add.12170
19.
Spanish National Focal: 2011 Spanish National Report. 2011. http://www.emcdda.europa.eu/html.cfm/index191736EN.html.
20.
Kaar SJ, Gao CX, Lloyd B, Smith K, Lubman DI: Trends in cannabis-related ambulance presentations from 2000 to 2013 in Melbourne, Australia. Drug Alcohol Depend 2015;155:24-30.
[PubMed]
https://doi.org/10.1016/j.drugalcdep.2015.08.021
21.
Di Forti M, Sallis H, Allegri F, Trotta A, Ferraro L, Stilo SA, et al: Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull 2014;40:1509-1517.
[PubMed]
https://doi.org/10.1093/schbul/sbt181
22.
Monshouwer K, Smit F, De Graaf R, van Os J, Vollebergh W: First cannabis use: does onset shift to younger ages? Findings from 1988 to 2003 from the Dutch National School Survey on Substance Use. Addiction 2005;100:963-970.
[PubMed]
https://doi.org/10.1111/j.1360-0443.2005.01088.x
23.
European Commission Directorate-General for General Communication: Flash Eurobarometer 401, Young People and Drugs Report, 2014, pp 1-162.
24.
Toxicodependência OE da D e: Cannabis production and markets in Europe. Obs Eur da Drog eToxicodependência 2012;274.
25.
King L: Understanding Cannabis Potency and Monitoring Cannabis Products in Europe, 2008.
26.
Niesink RJM, Rigter S, Koeter MW, Brunt TM: Potency trends of Δ9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15. Addiction 2015;110:1941-1950.
[PubMed]
https://doi.org/10.1111/add.13082
27.
EMCDDA: European Monitoring Centre for Drugs and Drug Addiction: Annual Report 2011. The State of the Drugs Problem in Europe, 2011, p 112.
28.
Adam C, Raschzok A: Cannabis policy and the uptake of treatment for cannabis-related problems. Drug Alcohol Rev 2017;36:171-177.
[PubMed]
https://doi.org/10.1111/dar.12401
29.
Winstock AR, Barratt M: Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample. Drug Alcohol Depend 2013;131:106-111.
[PubMed]
https://doi.org/10.1016/j.drugalcdep.2012.12.011
30.
Pirona A, Atkinson A, Sumnall H: Health Responses to New Psychoactive Substances, 2016, p 30.
31.
Evren C, Bozkurt M: Synthetic cannabinoids: crisis of the decade. Dusunen Adam 2013;26:1-11.
32.
Montanari L, Guarita B: Polydrug Use among Drug Treatment Clients in Europe. What Implications for Treatment? 20 Years of Monitoring - Key Indicators Expert Working Groups, 2015.
33.
Degenhardt L, Hall W: Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012;379:55-70.
[PubMed]
https://doi.org/10.1016/S0140-6736(11)61138-0
34.
Degenhardt L, Stockings E, Patton G, Hall WD, Lynskey M: The increasing global health priority of substance use in young people. Lancet Psychiatry 2016;3:251-264.
[PubMed]
https://doi.org/10.1016/S2215-0366(15)00508-8
© 2017 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2017
You do not currently have access to this content.